These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

714 related articles for article (PubMed ID: 33293694)

  • 1. Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression.
    Shi C; Yang EJ; Liu Y; Mou PK; Ren G; Shim JS
    Oncogene; 2021 Feb; 40(5):937-950. PubMed ID: 33293694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
    Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
    Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BET inhibition induces synthetic lethality in PTEN deficient colorectal cancers via dual action on p21
    Ren G; Chen J; Pu Y; Yang EJ; Tao S; Mou PK; Chen LJ; Zhu W; Chan KL; Luo G; Deng C; Shim JS
    Int J Biol Sci; 2024; 20(6):1978-1991. PubMed ID: 38617536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling.
    Zhang HT; Gui T; Sang Y; Yang J; Li YH; Liang GH; Li T; He QY; Zha ZG
    J Cell Biochem; 2017 Aug; 118(8):2182-2192. PubMed ID: 28059436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smad4 sensitizes colorectal cancer to 5-fluorouracil through cell cycle arrest by inhibiting the PI3K/Akt/CDC2/survivin cascade.
    Zhang B; Leng C; Wu C; Zhang Z; Dou L; Luo X; Zhang B; Chen X
    Oncol Rep; 2016 Mar; 35(3):1807-15. PubMed ID: 26647806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
    Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
    Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
    Yang L; Lei Q; Li L; Yang J; Dong Z; Cui H
    Clin Epigenetics; 2019 Dec; 11(1):199. PubMed ID: 31888761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
    Kodach LL; Bleuming SA; Peppelenbosch MP; Hommes DW; van den Brink GR; Hardwick JC
    Gastroenterology; 2007 Oct; 133(4):1272-81. PubMed ID: 17919499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromodomain and Extraterminal (BET) protein inhibition suppresses tumor progression and inhibits HGF-MET signaling through targeting cancer-associated fibroblasts in colorectal cancer.
    Wen D; Wang Y; Zhu Z; Huang Z; Cui L; Wu T; Liu CY
    Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165923. PubMed ID: 32800944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo.
    Shao Q; Kannan A; Lin Z; Stack BC; Suen JY; Gao L
    Cancer Res; 2014 Dec; 74(23):7090-102. PubMed ID: 25277525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aurora kinase A inhibition induces synthetic lethality in SMAD4-deficient colorectal cancer cells via spindle assembly checkpoint activation.
    Shi C; Tao S; Ren G; Yang EJ; Shu X; Mou PK; Liu Y; Dang Y; Xu X; Shim JS
    Oncogene; 2022 May; 41(19):2734-2748. PubMed ID: 35393542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms.
    Shi X; Mihaylova VT; Kuruvilla L; Chen F; Viviano S; Baldassarre M; Sperandio D; Martinez R; Yue P; Bates JG; Breckenridge DG; Schlessinger J; Turk BE; Calderwood DA
    Proc Natl Acad Sci U S A; 2016 Aug; 113(31):E4558-66. PubMed ID: 27432991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.
    Zhu X; Enomoto K; Zhao L; Zhu YJ; Willingham MC; Meltzer P; Qi J; Cheng SY
    Clin Cancer Res; 2017 Jan; 23(2):430-440. PubMed ID: 27440272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pien Tze Huang Inhibits Proliferation of Colorectal Cancer Cells through Suppressing PNO1 Expression and Activating p53/p21 Signaling Pathway.
    Cao LJ; Liu LY; Chen YQ; Han YY; Wei LH; Yao MY; Fang Y; Wu MZ; Cheng Y; Sferra TJ; Liu HX; Li L; Peng J; Shen AL
    Chin J Integr Med; 2024 Jun; 30(6):515-524. PubMed ID: 38216838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
    Bonazzoli E; Predolini F; Cocco E; Bellone S; Altwerger G; Menderes G; Zammataro L; Bianchi A; Pettinella F; Riccio F; Han C; Yadav G; Lopez S; Manzano A; Manara P; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Schlessinger J; Santin AD
    Clin Cancer Res; 2018 Oct; 24(19):4845-4853. PubMed ID: 29941483
    [No Abstract]   [Full Text] [Related]  

  • 18. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
    Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
    J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.
    Ma Y; Wang L; Neitzel LR; Loganathan SN; Tang N; Qin L; Crispi EE; Guo Y; Knapp S; Beauchamp RD; Lee E; Wang J
    Clin Cancer Res; 2017 Apr; 23(8):2027-2037. PubMed ID: 27678457
    [No Abstract]   [Full Text] [Related]  

  • 20. Suppression of c-Myc enhances p21
    Jeong YJ; Hoe HS; Cho HJ; Park KK; Kim DD; Kim CH; Magae J; Kang DW; Lee SR; Chang YC
    J Cell Biochem; 2018 Feb; 119(2):2036-2047. PubMed ID: 28833404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.